Scott B. Cameron

ORCID: 0000-0002-7045-1240
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Food Allergy and Anaphylaxis Research
  • Allergic Rhinitis and Sensitization
  • Asthma and respiratory diseases
  • Eosinophilic Esophagitis
  • Respiratory and Cough-Related Research
  • Cancer Immunotherapy and Biomarkers
  • Cancer-related Molecular Pathways
  • Respiratory viral infections research
  • CAR-T cell therapy research
  • Antimicrobial Resistance in Staphylococcus
  • Infant Health and Development
  • Cell death mechanisms and regulation
  • Immunotherapy and Immune Responses
  • Contact Dermatitis and Allergies
  • Drug-Induced Adverse Reactions
  • Ion Channels and Receptors
  • Toxin Mechanisms and Immunotoxins
  • T-cell and B-cell Immunology
  • Viral gastroenteritis research and epidemiology
  • Advanced Breast Cancer Therapies
  • Pediatric health and respiratory diseases
  • Immune Response and Inflammation
  • Immune cells in cancer
  • Thyroid Cancer Diagnosis and Treatment
  • Cancer Treatment and Pharmacology

University of British Columbia
2016-2025

British Columbia Children's Hospital
2020-2024

Sesame Workshop
2024

Cleveland Clinic
2021

Novartis (United States)
2012-2020

Kliniken Essen-Mitte
2018

Harvard University
2018

Royal Marsden Hospital
2018

Novartis Institutes for BioMedical Research
2017

Novartis (Switzerland)
2013-2017

BackgroundDespite the promise of oral immunotherapy (OIT) to treat food allergies, this procedure is associated with potential risk. There no current agreement about what elements should be included in preparatory or consent process.ObjectiveWe developed consensus recommendations OIT process considerations and patient-specific factors that addressed before initiating a information form.MethodsWe convened 36-member Preparing Patients for Oral Immunotherapy (PPOINT) panel allergy experts...

10.1016/j.jaci.2024.02.019 article EN cc-by-nc-nd Journal of Allergy and Clinical Immunology 2024-04-08

LCL161 antagonizes the function of inhibitor apoptosis proteins (IAPs), thereby promoting cancer cell death. This first-in-human dose-escalation study assessed maximum-tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics in patients with advanced solid tumors. A second part relative bioavailability a tablet versus solution formulation.LCL161 was administered orally, once weekly, on 21-day cycle to adult tumors by using an adaptive Bayesian logistic regression model overdose...

10.1200/jco.2013.52.3993 article EN Journal of Clinical Oncology 2014-08-12

Spartalizumab is a humanized IgG4κ monoclonal antibody that binds programmed death-1 (PD-1) and blocks its interaction with PD-L1 PD-L2. This phase 1/2 study was designed to assess the safety, pharmacokinetics, preliminary efficacy of spartalizumab in patients advanced or metastatic solid tumors.In 1 part study, 58 received spartalizumab, intravenously, at doses 1, 3, 10 mg/kg, administered every 2 weeks (Q2W), 3 5 mg/kg 4 (Q4W).Patients had wide range tumor types, most commonly sarcoma...

10.1136/jitc-2020-000530 article EN cc-by-nc Journal for ImmunoTherapy of Cancer 2020-03-01

During a nosocomial outbreak of infection due to vancomycin-resistant enterococci (VRE), rectal swabs that were collected weekly used identify and isolate VRE carriers. Over 6 months, 1,458 stool specimens from 724 high-risk patients cultured, 187 isolates recovered 61 patients; 96% the Enterococcus faecium. tended be isolated clinical identified as carriers by surveillance (P < .01). However, isolation cultures preceded for only ∼50% whom was recovered. Mortality greater .05) among than...

10.1093/clinids/21.1.45 article EN Clinical Infectious Diseases 1995-07-01

Eccrine sweat glands are essential for sweating and thermoregulation in humans. Loss-of-function mutations the Ca2+ release-activated (CRAC) channel genes ORAI1 STIM1 abolish store-operated entry (SOCE), patients with these CRAC suffer from anhidrosis hyperthermia at high ambient temperatures. Here we have shown that channel-deficient mice ectodermal tissue-specific deletion of Orai1 (Orai1K14Cre) or Stim1 Stim2 (Stim1/2K14Cre) failed to despite normal gland development. SOCE was absent...

10.1172/jci89056 article EN Journal of Clinical Investigation 2016-10-09

There are currently no targeted therapies approved for triple-negative breast cancer (TNBC). A tumor necrosis factor α ( TNFα)-based gene expression signature (GS) predictive of sensitivity to LCL161, inhibitor apoptosis antagonist, was translated into a clinical assay and evaluated in neoadjuvant trial.

10.1200/jco.2017.74.8392 article EN Journal of Clinical Oncology 2018-09-20

BackgroundAlthough oral immunotherapy (OIT) for food allergy is a reasonable treatment option, barriers to this procedure's implementation have not been extensively evaluated from patient perspective.ObjectiveWe the patients face during OIT administration, including anxiety and taste aversion, role of health care professionals, especially dietitians.MethodsA survey in Canada United States involved families currently enrolled programs.ResultsOf responses 379 participants, fear reaction was...

10.1016/j.jaip.2024.03.014 article EN cc-by-nc-nd The Journal of Allergy and Clinical Immunology In Practice 2024-03-14

AbstractGuinea pigs were administered 40 mg ethacry-nic acid per kg b.wt. and sacrificed at 30–48 minutes, 34- hours, 2 or 7 days post-drug. Cochlear potentials (EP CP) monitored before sacrifice. At the had decreased considerably, a marked edema plus cytological changes visible in stria vascularis. The recovered to about 75 % of their original value 3–4 hours; some cell recovery was visible, but still present. Potentials recorded from basal turn normal days, although strial cells showed...

10.3109/00016487709128819 article EN Acta Oto-Laryngologica 1977-01-01

6024 Background: Spartalizumab, a humanized IgG4 mAb, binds programmed death-1 (PD-1) with subnanomolar affinity and blocks interaction PD-L1/PD-L2. Anaplastic thyroid cancer (ATC) is an aggressive tumor, nearly 100% disease-specific mortality (NCCN Guidelines 2018) few treatment options. Methods: This Phase I/II, open-label, dose escalation/expansion study (NCT02404441) characterized the safety efficacy of spartalizumab in patients (pts) advanced solid tumors. The recommended II was 400 mg...

10.1200/jco.2018.36.15_suppl.6024 article EN Journal of Clinical Oncology 2018-05-20

Article1 July 2020Open Access Source Data STIM1-mediated calcium influx controls antifungal immunity and the metabolic function of non-pathogenic Th17 cells Sascha Kahlfuss orcid.org/0000-0001-8813-1061 Department Pathology, New York University Grossman School Medicine, York, NY, USA Search for more papers by this author Ulrike Kaufmann Axel R Concepcion Lucile Noyer Dimitrius Raphael Martin Vaeth Jun Yang Priya Pancholi Mate Maus James Muller Lina Kozhaya The Jackson Laboratory Genomic...

10.15252/emmm.201911592 article EN cc-by EMBO Molecular Medicine 2020-07-01

COVID-19 vaccination has been associated with anaphylaxis and hypersensitivity reactions. Infectious disease physicians allergists in the Canadian Special Immunization Clinic (SIC) Network developed guidance for evaluating patients adverse events following immunization (AEFI) including suspected hypersensitivity. This study evaluated management event recurrence subsequent vaccinations.

10.1016/j.vaccine.2024.06.045 article EN cc-by-nc Vaccine 2024-06-22

ABSTRACT The staphylococcal superantigen toxic shock syndrome toxin 1 (TSST-1) induces massive cytokine production, which is believed to be the key factor in pathogenesis of TSS. temporal sequence and kinetics both proinflammatory anti-inflammatory cytokines induced by TSST-1 human peripheral blood mononuclear cells were investigated. A panel loss-of-function single-amino-acid-substitution mutants TSST-1, previously demonstrated defective either major histocompatibility complex (MHC) class...

10.1128/iai.69.12.7544-7549.2001 article EN Infection and Immunity 2001-12-01
Coming Soon ...